Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 13, 2026Therapeutic Advances in HematologyOpen Access

Individualized decitabine dosing for post-HSCT maintenance in MDS and secondary AML from MDS: long-term outcomes from the PODAC trial and matched controls

View Full Paper
Ask AI
Bookmark
Share

Authors

SPSilvia ParkSCSuein ChoiSHSang Wook HanSoonchunhyang University

Discussion

Loading...

Member takes

Implication

Retrospective study evaluates long-term outcomes of individualized decitabine maintenance therapy in MDS after HSCT, indicating lower chronic GVHD incidence.

Key Points

  • The aim is to assess long-term outcomes of individualized decitabine therapy in patients post-HSCT for MDS or secondary AML from MDS.
  • Retrospective comparative study based on the phase I PODAC trial
  • Included 19 PODAC participants receiving individualized decitabine and 52 matched controls
  • Administered a median of 6 cycles of decitabine, starting at 5 mg/m²/day and escalating to 7 mg/m²/day
  • No significant differences in overall survival or relapse-free survival between PODAC and control groups
  • Lower incidence of moderate-to-severe chronic GVHD in the PODAC group
  • Decitabine maintenance was an independent predictor for improved chronic GVHD-free relapse-free survival (cCRFS)

Cite This Study

Park et al. (2026) studied this question.

synapsesocial.com/papers/69dc88f43afacbeac03eab10https://doi.org/10.1177/20406207261432568
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation2017 · 1,253 citations
  2. 2Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study2021 · 355 citations
  3. 3Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study2021 · 86 citations
  4. 4Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies2003 · 819 citations
  5. 5Low-Dose 5-Aza-2′-deoxycytidine Pretreatment Inhibits Experimental Autoimmune Encephalomyelitis by Induction of Regulatory T Cells2014 · 63 citations